Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(2.56)
# 2,227
Out of 4,959 analysts
50
Total ratings
31.25%
Success rate
0.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JSPR Jasper Therapeutics | Downgrades: Neutral | n/a | $2.93 | - | 5 | Jul 7, 2025 | |
| DRUG Bright Minds Biosciences | Assumes: Overweight | n/a | $43.96 | - | 1 | Jul 2, 2025 | |
| VERA Vera Therapeutics | Maintains: Overweight | $107 → $100 | $22.57 | +343.07% | 8 | May 7, 2025 | |
| VYGR Voyager Therapeutics | Reiterates: Overweight | n/a | $3.43 | - | 2 | Mar 12, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Overweight | n/a | $18.51 | - | 6 | Mar 7, 2025 | |
| PLRX Pliant Therapeutics | Reinstates: Neutral | n/a | $1.45 | - | 5 | Mar 4, 2025 | |
| KALV KalVista Pharmaceuticals | Reiterates: Overweight | n/a | $13.41 | - | 1 | Dec 9, 2024 | |
| ALEC Alector | Reiterates: Overweight | n/a | $2.52 | - | 5 | Nov 26, 2024 | |
| ANNX Annexon | Reiterates: Overweight | n/a | $2.31 | - | 9 | Nov 15, 2024 | |
| VSTM Verastem | Reiterates: Overweight | n/a | $9.08 | - | 1 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $24.30 | - | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $7.00 | -28.57% | 3 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.53 | +749.67% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $10.30 | -22.33% | 1 | Mar 20, 2023 |
Jasper Therapeutics
Jul 7, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.93
Upside: -
Bright Minds Biosciences
Jul 2, 2025
Assumes: Overweight
Price Target: n/a
Current: $43.96
Upside: -
Vera Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $107 → $100
Current: $22.57
Upside: +343.07%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.43
Upside: -
Arcturus Therapeutics Holdings
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $18.51
Upside: -
Pliant Therapeutics
Mar 4, 2025
Reinstates: Neutral
Price Target: n/a
Current: $1.45
Upside: -
KalVista Pharmaceuticals
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.41
Upside: -
Alector
Nov 26, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.52
Upside: -
Annexon
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.31
Upside: -
Verastem
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.08
Upside: -
Jun 27, 2024
Initiates: Overweight
Price Target: n/a
Current: $24.30
Upside: -
Sep 19, 2023
Reiterates: Overweight
Price Target: $5
Current: $7.00
Upside: -28.57%
Jul 17, 2023
Reiterates: Overweight
Price Target: $13
Current: $1.53
Upside: +749.67%
Mar 20, 2023
Reiterates: Overweight
Price Target: $8
Current: $10.30
Upside: -22.33%